Insights from 2023 ASH Annual Meeting

 

Leukemia
05:08

Insights from 2023 ASH Annual Meeting

Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOIA Study

FEATURING Paolo Ghia
  • 113 views
  • March 27, 2024
06:13

Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartinib vs. Standard Chemo

FEATURING Esther Oliva
  • 151 views
  • March 22, 2024
20:28

Insights from 2023 ASH Annual Meeting

Clinically-Relevant Updates in ALL in Adults

FEATURING Ryan Cassaday
  • 252 views
  • February 20, 2024
  • 1
08:45

Insights from 2023 ASH Annual Meeting

The Best of CLL: Highlights & Key Takeaways

FEATURING Victor Yazbeck
  • 522 views
  • January 24, 2024
  • 2
22:37

Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

FEATURING Talha Badar
  • 2,173 views
  • January 24, 2024
  • 14
21:20

Insights from 2023 ASH Annual Meeting

The Future Paradigm of HMA + Ven or Targeted Agents in AML: Sequencing and Triplet Combinations

FEATURING Justin Watts
  • 171 views
  • January 17, 2024
  • 5
06:43

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "NPM1-Mutated Myeloid Neoplasms - Outcomes With High-Intensity Chemo Regardless of Blast Percentage"

FEATURING Guillermo Montalban Bravo
  • 113 views
  • January 16, 2024
09:01

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatinib in Pts With Previously Treated Ph+ CML in Chronic or Accelerated Phase"

FEATURING Jorge Cortés
  • 87 views
  • January 16, 2024
  • 1
11:36

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Maintenance Rux Is Associated With Low Rates of cGVHD Requiring Systemic Treatment in Older Pts With AML/MDS Undergoing AlloHCT"

FEATURING Zachariah DeFilipp
  • 32 views
  • January 16, 2024
09:09

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax + Pegcrisantaspase in R/R AML - Overcoming Ven Resistance Through Glutamine Depletion"

FEATURING Yuchen Liu
  • 60 views
  • January 16, 2024
13:15

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Bezuclastinib (CGT9486), a Novel KIT D816V TKI, in Advanced Systemic Mastocytosis - Part 1 of the Apex Trial"

FEATURING Pankit Vachhani
  • 47 views
  • January 10, 2024
  • 1
13:07

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Treatment-Naïve, Higher-Risk MDS"

FEATURING Jacqueline Garcia
  • 361 views
  • December 29, 2023
  • 2
06:49

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Adults With ND Ph- B-ALL or T-ALL"

FEATURING Marlise R. Luskin
  • 179 views
  • December 29, 2023
  • 2
07:43

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Inotuzumab Ozogamicin for R/R ALL in Adults"

FEATURING Marlise R. Luskin
  • 25 views
  • December 29, 2023
04:45

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The Impact of Inotuzumab Ozogamicin Treatment on Brexu-Cel Outcomes in Adults With R/R B-ALL"

FEATURING Ibrahim Aldoss
  • 163 views
  • December 29, 2023
05:38

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Revumenib Monotherapy in Pts With R/R KMT2Ar Acute Leukemia From the AUGMENT-101 Study"

FEATURING Ibrahim Aldoss
  • 101 views
  • December 29, 2023
09:19

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in R/R CLL From the CLL2-BAAG Trial"

FEATURING Moritz Fürstenau
  • 61 views
  • December 29, 2023
13:31

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "COVALENT-101 Study - Covalent Menin Inhibitor BMF-219 in Patients With R/R Acute Leukemia"

FEATURING Jeffrey Lancet
  • 86 views
  • December 27, 2023
01:44

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Optimizing Outcomes With Myeloablative Conditioning in Older Patients - Precision Engineered Orca-T in Patients >55 y.o. With Heme Malignancies"

FEATURING Caspian Oliai
  • 19 views
  • December 22, 2023
07:55

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Patients With CML-CP Treated With Asciminib in US Clinical Practice"

FEATURING Ehab Atallah
  • 633 views
  • December 22, 2023
  • 3
10:08

Insights from 2023 ASH Annual Meeting

Comparison of Venetoclax Based Treatments for Patients With R/R CLL

FEATURING Benjamin Heyman
  • 296 views
  • December 22, 2023
18:27

Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: QuANTUM-First - Safety by Treatment Phase and by Age in ND Patients

FEATURING Harry P. Erba
  • 208 views
  • December 22, 2023
18:01

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Primetime?"

FEATURING Joanna Rhodes
  • 329 views
  • December 22, 2023
  • 2
04:21

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Improving Long-Term Outcomes With Intensive Induction Chemotherapy for Patients With AML"

FEATURING Christoph Röllig
  • 134 views
  • December 22, 2023
03:03

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Pts With Heavily Pretreated/Refractory CML and Ph+ ALL"

FEATURING Elias Jabbour
  • 124 views
  • December 21, 2023
11:00

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Oral Decitabine/Cedazuridine (ASTX727) & Venetoclax in Combination With IDH1 or IDH2 Inhibitor Therapy for IDHmut AML"

FEATURING Himachandana Atluri
  • 28 views
  • December 20, 2023
11:02

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Prednisone for BCR-ABL1+ ALL and Blast Phase CML in Adults"

FEATURING Marlise R. Luskin
  • 205 views
  • December 20, 2023
08:32

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Treatment for 1L CP-CML"

FEATURING David Yeung
  • 119 views
  • December 20, 2023
14:40

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "AYAs With ALL - Treatment Approaches and Ongoing Challenges"

FEATURING Emily Curran
  • 54 views
  • December 19, 2023
14:10

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Relapse Incidence Post Unrelated alloSCT With Post-SCT Cyclophosphamide vs. Conventional Anti-GVHD Prophylaxis in AML Pts - A ALWP/EMBT Study"

FEATURING Arnon Nagler
  • 30 views
  • December 19, 2023
06:56

Insights from 2023 ASH Annual Meeting

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/R CLL: A Matching-Adjusted Indirect Comparison

FEATURING Mazyar Shadman
  • 822 views
  • December 19, 2023
  • 1
07:04

Insights from 2023 ASH Annual Meeting

Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients With CLL/SLL

FEATURING Mazyar Shadman
  • 402 views
  • December 19, 2023
  • 3
08:11

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosidenib or Venetoclax in Newly Diagnosed Patients With IDH1mut AML - A RWE Study"

FEATURING Alexander Ambinder
  • 50 views
  • December 19, 2023
08:26

Insights from 2023 ASH Annual Meeting

CLL/SLL Treatment With Post-cBTKi Pirtobrutinib: 30 Months Follow-Up & Subgroup Analysis With/Without Prior BCL2i From the Ph1/2 BRUIN Study

FEATURING Jennifer Woyach
  • 398 views
  • December 19, 2023
  • 2
06:17

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Revumenib Maintenance Therapy Following Revumenib-Induced Remission & Transplant in Acute Leukemias"

FEATURING Andrius Zucenka
  • 69 views
  • December 18, 2023
05:12

Insights from 2023 ASH Annual Meeting

R/R CLL Treated With Fixed-Duration Pirtobrutinib Combined With Venetoclax ± Rituximab: Updated BRUIN Study Results Including MRD Data

FEATURING Nirav Shah
  • 410 views
  • December 18, 2023
  • 2
07:06

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effectiveness of Venetoclax-Based Therapy After BTKis in CLL"

FEATURING Nilanjan Ghosh
  • 147 views
  • December 17, 2023
08:18

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effect of Ibrutinib Flexible Dosing Strategies on TTNT in CLL From a Largely Community-Based Claims Database"

FEATURING Nilanjan Ghosh
  • 101 views
  • December 17, 2023
  • 1
07:22

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Hypertension in Pts With CLL and Other Heme Malignancies Treated With Acalabrutinib"

FEATURING Alessandra Ferrajoli
  • 172 views
  • December 17, 2023
09:38

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Long-Term Analysis of Lenalidomide & Rituximab for the Treatment of CLL"

FEATURING Chung-Jiah Chen
  • 31 views
  • December 17, 2023
07:18

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL"

FEATURING Kerry Rogers
  • 70 views
  • December 17, 2023
  • 1
07:32

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Understanding Differential Technologies for Detection of MRD in AML and How to Incorporate Into Clinical Practice"

FEATURING Jacqueline Cloos
  • 83 views
  • December 15, 2023
10:32

Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: Quizartinib, Venetoclax, & Decitabine Triple Combination

FEATURING Musa Yilmaz
  • 140 views
  • December 15, 2023
07:11

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Regimen of CC-486 and Venetoclax For R/R AML"

FEATURING Maria Amaya
  • 157 views
  • December 14, 2023
06:57

Insights from 2023 ASH Annual Meeting

TN-CLL/SLL: Combination Treatment With Sonrotoclax (BGB-11417), a 2nd-Gen BCL2i, and Zanubrutinib

FEATURING Mary Ann Anderson
  • 182 views
  • December 14, 2023
05:28

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Performance of the Molecular International Prognostic Scoring System in HMA-Treated Patients With MDS"

FEATURING Kelly Chien
  • 73 views
  • December 13, 2023
  • 1
10:38

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not Survival in Pts With CMML Treated With Hypomethylating Agents"

FEATURING Douglas Tremblay
  • 35 views
  • December 13, 2023